TN2015000006A1 - Pharmaceutical composition having improved flowability. medicinal agent, and method for producing and using same - Google Patents

Pharmaceutical composition having improved flowability. medicinal agent, and method for producing and using same

Info

Publication number
TN2015000006A1
TN2015000006A1 TNP2015000006A TN2015000006A TN2015000006A1 TN 2015000006 A1 TN2015000006 A1 TN 2015000006A1 TN P2015000006 A TNP2015000006 A TN P2015000006A TN 2015000006 A TN2015000006 A TN 2015000006A TN 2015000006 A1 TN2015000006 A1 TN 2015000006A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical composition
producing
improved flowability
same
octylphenyl
Prior art date
Application number
TNP2015000006A
Other languages
English (en)
Inventor
Alexandre Vasilievich Ivachtchenko
Alexandre Viktorovich Demin
Original Assignee
Alexandre Vasilievich Ivachtchenko
Alla Chem Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49446598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2015000006(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexandre Vasilievich Ivachtchenko, Alla Chem Llc filed Critical Alexandre Vasilievich Ivachtchenko
Publication of TN2015000006A1 publication Critical patent/TN2015000006A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/074—Filling capsules; Related operations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TNP2015000006A 2012-07-11 2015-01-07 Pharmaceutical composition having improved flowability. medicinal agent, and method for producing and using same TN2015000006A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2012129101/15A RU2496486C1 (ru) 2012-07-11 2012-07-11 Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
PCT/RU2013/000572 WO2014011083A2 (fr) 2012-07-11 2013-07-05 Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application

Publications (1)

Publication Number Publication Date
TN2015000006A1 true TN2015000006A1 (en) 2016-06-29

Family

ID=49446598

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2015000006A TN2015000006A1 (en) 2012-07-11 2015-01-07 Pharmaceutical composition having improved flowability. medicinal agent, and method for producing and using same

Country Status (22)

Country Link
US (1) US9370576B2 (fr)
EP (1) EP2873416B1 (fr)
JP (1) JP6093015B2 (fr)
KR (1) KR20150036228A (fr)
CN (1) CN104487063B (fr)
AP (1) AP2014008171A0 (fr)
BR (1) BR112015000544A2 (fr)
CL (1) CL2015000052A1 (fr)
CO (1) CO7310521A2 (fr)
EA (1) EA027712B1 (fr)
GE (1) GEP201606571B (fr)
IL (1) IL236562A0 (fr)
IN (1) IN2015DN00130A (fr)
MA (1) MA37693B1 (fr)
MX (1) MX2015000467A (fr)
PE (1) PE20150632A1 (fr)
RU (1) RU2496486C1 (fr)
SG (1) SG11201500178QA (fr)
TN (1) TN2015000006A1 (fr)
UA (1) UA113216C2 (fr)
WO (1) WO2014011083A2 (fr)
ZA (1) ZA201409481B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110398A1 (fr) 2013-01-10 2014-07-17 Edh Us Llc Mesure de vitesse de rotation de balle
RU2611415C1 (ru) * 2015-11-17 2017-02-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты)
WO2020005189A2 (fr) * 2018-06-27 2020-01-02 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques solides d'administration par voie orale comprenant du tériflunomide

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0627406T3 (da) 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
HU224814B1 (en) 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
RU2358717C2 (ru) 2002-05-16 2009-06-20 Новартис Аг Применение средств, связывающих edg-рецептор, в лечении ракового заболевания
HUE028247T2 (en) * 2003-04-08 2016-12-28 Novartis Ag A solid oral composition comprising S1P receptor agonist and sugar alcohol
WO2005025553A2 (fr) * 2003-09-12 2005-03-24 Neuronova Ab Traitement de maladies ou de lesions du systeme nerveux avec le fty720
PL1773307T3 (pl) 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
MXPA05008573A (es) 2005-08-12 2007-02-12 Leopoldo Espinosa Abdala Composicion de isoflavonas para tratamiento de los sintomas y trastornos fisiologicos de la menopausia.
EP1923058A1 (fr) * 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique enrobée comprenant un agoniste ou un modulateur de S1P
CN102579387A (zh) * 2006-09-26 2012-07-18 诺瓦提斯公司 包含s1p调节剂的药物组合物
EP3120833A1 (fr) * 2007-10-12 2017-01-25 Novartis Ag Compositions comprenant des modulateurs de récepteur de sphingosine 1 (s1p) phosphate
WO2011131369A1 (fr) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod sous la forme de solution solide
EP2560618A1 (fr) * 2010-04-22 2013-02-27 Ratiopharm GmbH Fingolimod granulé fondu

Also Published As

Publication number Publication date
CN104487063B (zh) 2017-05-10
WO2014011083A2 (fr) 2014-01-16
EP2873416B1 (fr) 2017-04-26
EP2873416A4 (fr) 2016-03-16
JP6093015B2 (ja) 2017-03-08
EA201500096A1 (ru) 2015-05-29
RU2496486C1 (ru) 2013-10-27
KR20150036228A (ko) 2015-04-07
CL2015000052A1 (es) 2015-09-04
UA113216C2 (xx) 2016-12-26
IL236562A0 (en) 2015-02-26
EA027712B1 (ru) 2017-08-31
BR112015000544A2 (pt) 2017-10-24
US9370576B2 (en) 2016-06-21
US20150335754A1 (en) 2015-11-26
GEP201606571B (en) 2016-11-10
WO2014011083A3 (fr) 2014-03-06
SG11201500178QA (en) 2015-03-30
EP2873416A2 (fr) 2015-05-20
CN104487063A (zh) 2015-04-01
PE20150632A1 (es) 2015-05-20
IN2015DN00130A (fr) 2015-05-29
MA37693B1 (fr) 2017-01-31
JP2015522068A (ja) 2015-08-03
MX2015000467A (es) 2015-06-05
MA37693A1 (fr) 2016-06-30
AP2014008171A0 (en) 2014-12-31
ZA201409481B (en) 2016-02-24
CO7310521A2 (es) 2015-06-30

Similar Documents

Publication Publication Date Title
PH12020550341A1 (en) Niraparib formulations
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
MX2015009986A (es) Agonistas del receptor de esfingosina-1-fosfato, metodos para prepararlos y composiciones farmaceuticas que contienen los mismos como un agente activo.
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
MY175781A (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
MX335944B (es) Composiciones que comprenden sulfato de salbutamol.
BR112013017750A8 (pt) nanocápsulas com revestimento polimérico
BR112015020707A2 (pt) formulações transdermicas
CL2013002810A1 (es) Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple.
TN2015000006A1 (en) Pharmaceutical composition having improved flowability. medicinal agent, and method for producing and using same
WO2014011750A8 (fr) Formulations de laquinimod sans agent alcalinisant
MX364680B (es) Composicion solida para administracion oral que contiene acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX370890B (es) Composición que comprende sulfato de salbutamol.
CL2018003688A1 (es) Método y equipo de preparación de una composición de micropartículas
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
BR112018067663A2 (pt) compostos derivados de sulfamato, processos para preparação dos mesmos e seus usos
MX2022006502A (es) Composiciones farmaceuticas.